Acute pulmonary embolism: comment on "time trends in pulmonary embolism in the United States".

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany.Journal of thrombosis and thrombolysis · 2015
   Article
2. Subsegmental pulmonary embolism: is the emperor still naked?La Radiologia medica · 2013
   Article
3. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found.BMJ (Clinical research ed.) · 2013
   Article
4. Effectiveness of a novel and scalable clinical decision support intervention to improve venous thromboembolism prophylaxis: a quasi-experimental study.BMC medical informatics and decision making · 2012
   Article

Corrections and comments

• Comment on
  Time trends in pulmonary embolism in the United States: evidence of overdiagnosis.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as